The ARIAA trial tested the utility of IV abatacept in individuals ACPA+ arthralgia patients with subclinical inflammation and showed abatacept to decrease MRI inflammation, clinical symptoms, and risk of future RA development. https://t.co/PdYLKwT0z9 https://t.co/O8uHxzleIK